Triptorelin (Trelstar/Decapeptyl): Complete Research Profile — FDA-Approved GnRH Agonist for Gonadotropin Suppression and HPG Axis Research (2026)

# Triptorelin (Trelstar/Decapeptyl): Complete Research Profile — FDA-Approved GnRH Agonist for Gonadotropin Suppression and HPG Axis Research (2026)

Triptorelin — marketed as Trelstar, Decapeptyl, and Diphereline — is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) that stands as one of the most extensively studied GnRH superagonists in biomedical research. FDA-approved for advanced prostate cancer and endorsed in guidelines for endometriosis and central precocious puberty, triptorelin achieves approximately 100-fold greater GnRH receptor binding affinity than native GnRH alongside dramatically improved metabolic stability — making it a foundational pharmacological probe for investigating the hypothalamic–pituitary–gonadal (HPG) axis.

> Research Use Only (RUO): Triptorelin is an FDA-approved therapeutic compound studied in research contexts for its mechanisms of GnRH receptor activation, HPG axis modulation, and hormone-sensitive disease biology. All information below pertains to preclinical, translational, and clinical research contexts. This content is not medical advice.

---

Molecular Structure and Design

Triptorelin is a decapeptide with the sequence:

pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂

The defining structural feature is the substitution of glycine at position 6 (present in native GnRH) with D-tryptophan (D-Trp⁶). This modification produces three pharmacologically critical consequences:

1. Proteolytic resistance — Endopeptidases that cleave native GnRH between positions 5–6 and 6–7 cannot efficiently hydrolyze the D-amino acid configuration, extending biological half-life from ~2–4 minutes to several hours.

2. Enhanced receptor binding — D-Trp⁶ enables a more favorable receptor-bound conformation, increasing binding affinity approximately 100-fold over native GnRH.

3. Superagonist behavior — Sustained, high-affinity receptor occupancy drives paradoxical desensitization, the mechanism central to most triptorelin research applications.

The C-terminal amide (-Gly-NH₂) further protects against carboxypeptidase degradation. Together, these design features make triptorelin a superior pharmacological probe compared to native GnRH in both in vitro receptor assays and in vivo animal models.

Three decapeptide GnRH agonists are used in research: nafarelin, goserelin, and triptorelin — distinguished from the nonapeptide analogs leuprolide, buserelin, and histrelin, which lack the C-terminal glycine amide.

---

Mechanism of Action: Biphasic GnRH Receptor Pharmacology

Phase 1: Initial Stimulation ("Flare")

Upon first exposure, triptorelin binds the GnRH receptor (GnRHR) — a Gq/11-coupled GPCR expressed on pituitary gonadotrophs — and activates intracellular signaling cascades including phospholipase C, IP₃/DAG, and PKC pathways. This triggers robust release of:

• •Luteinizing hormone (LH)
• •Follicle-stimulating hormone (FSH)

The resulting LH surge in males transiently elevates testosterone (peaking around day 2–4 with depot formulations), while in females it triggers estrogen and progesterone fluctuations. This acute flare phase persists for 1–2 weeks with depot formulations — a clinically important consideration in prostate cancer research, where a transient testosterone surge can trigger tumor flare.

Phase 2: Receptor Desensitization and HPG Suppression

Continuous GnRHR occupancy by triptorelin — unlike the pulsatile GnRH secretion of normal physiology — induces a cascade of desensitization events:

1. Receptor uncoupling from G-proteins (minutes to hours)

2. Receptor internalization and downregulation (hours to days)

3. Post-receptor signal desensitization (days to weeks)

4. Reduced gonadotropin synthesis and release (sustained throughout treatment)

After 2–4 weeks of continuous depot administration, LH and FSH levels fall below baseline. In males, serum testosterone reaches castrate levels (<50 ng/dL). In females, estradiol falls to postmenopausal levels. This pharmacological castration is fully reversible upon discontinuation, as demonstrated by recovery of gonadotropin pulsatility and sex steroid production in experimental models.

A 2025 study in rats confirmed that triptorelin-induced testicular atrophy is reversible and focal, with sperm production preserved despite the period of androgen suppression — an important finding for fertility research applications (PMID 40724815).

---

Formulation Details: Pamoate Microsphere Depot Technology

Triptorelin's research utility is inseparable from its microsphere depot technology. The Trelstar formulation encapsulates triptorelin pamoate in biodegradable PLGA (poly(lactic-co-glycolic acid)) microspheres that slowly erode after intramuscular injection, releasing drug over weeks to months.

Available Depot Formulations

The pamoic acid counterion contributes hydrophobicity that enables stable PLGA microsphere formulations — the same approach used in Decapeptyl and Diphereline (triptorelin acetate and pamoate formulations marketed internationally).

Reconstitution Protocol for Research Use

Triptorelin depots are supplied as lyophilized powder requiring reconstitution immediately before use:

1. Reconstitute with 2 mL Sterile Water for Injection using the dedicated MIXJECT system or equivalent aseptic technique

2. Draw solvent into syringe via a 20G reconstitution needle; transfer to the powder vial

3. Swirl gently from side to side until a homogeneous milky suspension forms — do not invert the vial

4. Verify no unsuspended powder remains visible

5. Draw the suspension back into the syringe; switch to a fresh 20G injection needle

6. Administer immediately — microspheres begin to settle and aggregate within minutes; discard any unused portion

7. Store lyophilized product refrigerated at 2–8°C (36–46°F)

This single-use, immediate-administration requirement is critical for research protocols; any delay after reconstitution compromises dose accuracy due to microsphere sedimentation.

Pharmacokinetics of Depot Formulations

Following IM injection of Trelstar 3.75 mg, serum testosterone peaks around day 4, then declines to castrate levels by week 4. For the 11.25 mg quarterly depot, testosterone peaks around day 2 then falls to suppressive levels by week 4 — maintained through week 12 in most research subjects. This early-peak/sustained-suppression kinetic profile is a defining feature of PLGA microsphere delivery that distinguishes depot triptorelin from daily subcutaneous peptide formulations.

---

Research Applications

1. Hormone-Sensitive Cancer Research

Triptorelin is one of the most studied GnRH analogs in cancer biology, particularly for androgen-sensitive and estrogen-sensitive tumor models.

#### Prostate Cancer Models

Androgen deprivation via HPG axis suppression is the cornerstone of androgen-sensitive prostate cancer research. Triptorelin's ability to reduce testosterone to castrate levels within 2–4 weeks makes it a standard pharmacological tool in:

• •Androgen deprivation research models — investigating castration-sensitive vs. castration-resistant transitions
• •Receptor sensitivity studies — characterizing androgen receptor (AR) expression changes during androgen suppression
• •Combination therapy protocols — studying additive or synergistic effects with antiandrogens
• •Pharmacokinetic modeling — evaluating new controlled-release formulations for sustained suppression

A randomized trial of 277 men with advanced prostate cancer compared triptorelin 3.75 mg against a comparator GnRH agonist over 9 months, documenting reliable castrate testosterone suppression — the foundational dataset for its FDA approval in this indication.

Research has documented that triptorelin achieves deeper testosterone suppression than some comparators: in a direct comparison study, 93.2% of triptorelin-treated patients reached the ultra-low threshold of <10 ng/dL vs. 86.4% for leuprolide and 54.2% for goserelin (PMID 31294133).

#### Anti-Proliferative Mechanisms Beyond HPG Suppression

GnRH receptors are expressed directly on many cancer cell lines — including breast, ovarian, prostate, and endometrial cancer — suggesting pituitary-independent anti-tumor effects. Studies have identified methylated triptorelin analogs with high potency as anti-proliferative agents, opening research avenues for:

• •Direct GnRHR-mediated apoptosis signaling
• •Peptide-drug conjugate development using triptorelin as tumor-targeting moiety
• •Structure-activity relationship (SAR) studies of GnRH analogs in oncology (PMID 24490142)

2. Endometriosis and Estrogen-Dependent Tissue Research

Endometriosis, uterine fibroids (leiomyomas), and adenomyosis are driven by estrogen-dependent tissue proliferation. Triptorelin's induction of a hypoestrogenic state through pituitary desensitization makes it a key pharmacological tool for studying these conditions in preclinical models:

• •Lesion regression models — documenting the response of endometriotic implants to sex steroid withdrawal
• •Fibrotic tissue biology — studying leiomyoma growth dynamics under estrogen-depleted conditions
• •Recurrence biology — investigating molecular mechanisms of endometriosis recurrence after GnRH agonist cessation
• •Add-back research — studying co-administration with estrogen/progestogen to maintain suppression while mitigating bone loss

3. Central Precocious Puberty (CPP) Models

Central precocious puberty — defined as premature HPG axis activation before age 8 in girls and 9 in boys — involves pathologically early GnRH pulsatility. Triptorelin is a primary research tool for:

• •Pubertal timing studies — characterizing neuroendocrine mechanisms that regulate pubertal onset
• •GnRH receptor ontogeny research — studying developmental changes in pituitary GnRHR sensitivity
• •Long-term hormonal programming — investigating whether early HPG suppression affects adult reproductive outcomes

A clinical trial administered triptorelin pamoate 11.25 mg at baseline and month 3, demonstrating GnRH-stimulated LH levels ≤3 IU/L as the primary suppression endpoint in pediatric subjects (NCT00564850). A comparative study of leuprolide and triptorelin in idiopathic CPP showed comparable efficacy in LH suppression and bone age advancement prevention, with mild menopausal-like side effects in approximately 41.8% of patients (PMC10229807).

4. Gender-Affirming Care Research

Triptorelin holds historical significance in gender medicine: in 1998, physicians in the Netherlands published the first report of a transgender patient treated with triptorelin for puberty suppression — establishing the foundational "Dutch model" that was later incorporated into WPATH and Endocrine Society guidelines.

Research applications in this domain include:

• •Puberty suppression efficacy — A prospective study of 116 transgender adolescents documented gonadotropin and estradiol suppression within 3 months of triptorelin initiation, with testosterone suppression achieved in AMAB adolescents
• •Psychological outcomes research — Studies of 36 transgender adolescents showed gender-affirming physical changes from triptorelin treatment were associated with improvement in body uneasiness and psychological functioning
• •Long-term developmental research — The 2025 rat study using triptorelin initiated before puberty onset (mimicking timing in transgender girls) found reversible and focal testicular effects, supporting fertility-related safety research in pubertal suppression models (PMID 40724815)
• •Bone health studies — Investigating bone mineral density effects of HPG suppression during adolescence, informing add-back hormone strategies

A 2024 systematic review (PMC12116301) covering studies from 2011–2024 confirmed GnRH agonists including triptorelin are effective for puberty suppression in transgender and gender-diverse youth, while noting that long-term evidence on efficacy and safety continues to evolve.

5. Fertility Preservation Research

Triptorelin is used in IVF protocols and fertility preservation research to synchronize follicular development or prevent premature LH surges in controlled ovarian stimulation. Research applications include:

• •Follicular synchronization — using the initial LH flare to coordinate cohort development before gonadotropin stimulation
• •Ovarian protection — studying GnRH agonist co-treatment during chemotherapy to preserve ovarian reserve
• •Pituitary downregulation protocols — establishing long-protocol IVF models for comparative research

---

Comparison to Other GnRH Agonists

Triptorelin's place within the GnRH agonist class is best understood through systematic comparison. All major agents share the same fundamental biphasic mechanism, but differ in formulation, route, peptide length, and clinical niche.

Key differentiators:

• •Triptorelin vs. Leuprolide: Both are the most commonly used agents in CPP research, with comparable LH suppression efficacy and similar tolerability profiles. Triptorelin achieves statistically deeper testosterone suppression (<10 ng/dL) in prostate cancer models. Leuprolide has the broadest published research base and the most formulation options including a 4-month depot.

• •Triptorelin vs. Histrelin: Histrelin's subdermal implant provides 12-month continuous suppression without repeated injections — advantageous for long-duration research protocols. Triptorelin's injectable depot avoids surgical implantation but requires more frequent dosing.

• •Triptorelin vs. Nafarelin: Nafarelin is the only intranasal GnRH agonist, enabling twice-daily dosing without injections — uniquely suited for endometriosis research in outpatient models. Triptorelin's injectable depot provides more consistent pharmacokinetics, avoiding the bioavailability variability inherent to mucosal absorption.

• •Triptorelin vs. Goserelin: Goserelin's subcutaneous implant rod provides a different release mechanism (polymer erosion vs. PLGA microspheres). Goserelin has demonstrated superior PSA suppression data in some prostate cancer studies; triptorelin achieves deeper testosterone nadir in direct comparisons.

• •Comparison to GnRH Antagonists: Unlike GnRH agonists, antagonists (cetrorelix, ganirelix, degarelix) produce immediate suppression without the initial flare — eliminating testosterone surge risk in prostate cancer research. The absence of flare makes antagonists preferred in certain oncology protocols, while agonists like triptorelin remain dominant in endometriosis and CPP research where the flare is clinically manageable. See the GnRH Antagonist Research Profile for a full mechanistic comparison.

---

Dosing in the Research Literature

Standard Depot Doses (from Published Literature)

Research-Relevant Pharmacokinetic Notes

• •Testosterone nadir: Reached at ~week 4 with monthly depot; maintained through dosing interval
• •Flare duration: Acute LH/FSH surge lasts 1–2 weeks with depot formulations — a critical confounder for early experimental endpoints
• •Reversibility: Gonadotropin pulsatility recovers within 1–6 months of discontinuation depending on treatment duration

---

Supplier Availability and Research Market

Triptorelin is commercially available through multiple research peptide suppliers as both the acetate and pamoate salt forms. Researchers accessing triptorelin through the research peptide market should note:

• •Salt form matters: Triptorelin pamoate provides slower in-solution release characteristics; triptorelin acetate is more commonly used for non-depot research formulations
• •Purity verification: Request CoA with HPLC purity ≥98% and MS confirmation of correct molecular weight (1,311.5 Da for triptorelin free base)
• •Lyophilized stability: Store at -20°C protected from moisture; properly lyophilized triptorelin is stable for years; reconstituted solutions should be used within 24 hours if stored at 4°C
• •Reconstitution for research: For non-depot research applications, reconstitute in sterile water or PBS at 1 mg/mL; filter-sterilize (0.22 µm) before use in cell culture

Peptides.SO maintains a curated supplier directory where researchers can compare vendors offering verified triptorelin with independent quality documentation.

---

Key Research Citations

1. Triptorelin testicular reversibility (2025): The GnRH agonist triptorelin causes reversible, focal, and partial testicular atrophy in rats, maintaining sperm production. PMC12295780 — PMID 40724815

2. Triptorelin vs. leuprolide vs. goserelin for testosterone suppression (2019): Effectiveness of three different LHRH agonists in chemical castration of patients with prostate cancer. Triptorelin achieved deepest nadir (93.2% at <10 ng/dL). PubMed — PMID 31294133

3. Anti-proliferative GnRHR-mediated mechanisms (2014): Methylated triptorelin analogs with anti-proliferative activity on cancer cell lines through GnRH receptor binding. PMC3906704 — PMID 24490142

4. Triptorelin vs. leuprolide in CPP (2023): Leuprolide and triptorelin in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study. PMC10229807 — PMID available via PMC

5. GnRH agonists in transgender youth (2024 systematic review): Use of gonadotropin-releasing hormone agonists in transgender and gender-diverse youth. PubMed/EMBASE search Feb 2011–Feb 2024. — PMC12116301

6. Puberty suppression in gender dysphoria (2024): Puberty suppression in adolescents with gender dysphoria: an emerging issue with multiple implications. Frontiers in Endocrinology — PMC11235884

7. GnRH agonist systematic review for prostate cancer (2018): Are all GnRH agonists equivalent for prostate cancer? 16 direct comparative trials reviewed. BJU International — DOI 10.1111/bju.14168

---

Related Research Profiles

The GnRH agonist class shares a common mechanism. For comparative research contexts, see:

• •Gonadorelin (GnRH): Master Reproductive Decapeptide — the endogenous ligand triptorelin mimics
• •Gonadorelin Dosage & Protocol Guide — practical protocols for native GnRH research
• •Leuprolide Acetate (Lupron) Research Profile — the most widely studied GnRH agonist
• •Histrelin (Supprelin LA/Vantas) Research Profile — annual subdermal implant GnRH agonist
• •Nafarelin (Synarel) Research Profile — the only intranasal GnRH agonist
• •GnRH Antagonists (Cetrorelix, Ganirelix, Degarelix) — immediate suppression without flare

---

Research Use Only. Triptorelin is an FDA-approved pharmaceutical compound. This article is provided for educational and research context only and does not constitute medical advice. Consult applicable regulatory guidelines for research use in your jurisdiction.